HC Wainwright Has Pessimistic Outlook of Vericel Q4 Earnings

Vericel Co. (NASDAQ:VCEL) – Research analysts at HC Wainwright lowered their Q4 2024 EPS estimates for shares of Vericel in a report released on Friday, November 8th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings per share of $0.37 for the quarter, down from their previous estimate of $0.38. HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Vericel’s current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Vericel’s Q3 2025 earnings at $0.09 EPS.

Vericel (NASDAQ:VCEL) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.03. The company had revenue of $57.91 million for the quarter, compared to analyst estimates of $55.32 million. Vericel had a net margin of 1.56% and a return on equity of 1.48%.

Several other research firms have also weighed in on VCEL. Canaccord Genuity Group started coverage on shares of Vericel in a research note on Friday, August 9th. They set a “buy” rating and a $57.00 price objective on the stock. Canaccord Genuity Group started coverage on shares of Vericel in a research note on Friday, August 9th. They issued a “buy” rating and a $57.00 price target on the stock. Stephens lifted their price target on shares of Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. TD Cowen lifted their price target on shares of Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, August 27th. Finally, Truist Financial lifted their price target on shares of Vericel from $56.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Vericel presently has an average rating of “Moderate Buy” and a consensus price target of $57.71.

Vericel Price Performance

Vericel stock opened at $55.89 on Monday. The company’s 50 day simple moving average is $44.37 and its 200 day simple moving average is $46.49. Vericel has a fifty-two week low of $32.31 and a fifty-two week high of $57.81. The firm has a market capitalization of $2.76 billion, a price-to-earnings ratio of 946.33 and a beta of 1.66.

Insider Activity

In other news, CEO Dominick Colangelo sold 17,500 shares of Vericel stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total value of $724,150.00. Following the sale, the chief executive officer now directly owns 220,937 shares in the company, valued at $9,142,373.06. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Steven C. Gilman sold 5,833 shares of the business’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $41.36, for a total transaction of $241,252.88. Following the transaction, the director now directly owns 11,000 shares in the company, valued at approximately $454,960. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Dominick Colangelo sold 17,500 shares of the business’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total transaction of $724,150.00. Following the transaction, the chief executive officer now owns 220,937 shares in the company, valued at approximately $9,142,373.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 29,166 shares of company stock worth $1,200,764 over the last ninety days. Insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Vericel

Institutional investors have recently added to or reduced their stakes in the company. UniSuper Management Pty Ltd acquired a new position in Vericel during the first quarter worth $595,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Vericel by 10.9% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,021,695 shares of the biotechnology company’s stock worth $53,149,000 after purchasing an additional 100,797 shares during the period. Silvercrest Asset Management Group LLC bought a new position in Vericel during the first quarter worth $6,538,000. Scholtz & Company LLC bought a new position in Vericel during the second quarter worth $1,357,000. Finally, Allspring Global Investments Holdings LLC boosted its position in Vericel by 6.5% during the second quarter. Allspring Global Investments Holdings LLC now owns 420,643 shares of the biotechnology company’s stock worth $19,299,000 after purchasing an additional 25,626 shares during the period.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.